Streetbeat News

Stock Prices

ETSY

Etsy shares are experiencing an upward trend following the release of their Q3 financial results, which surpassed market expectations.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:45 pm

ENVX

Enovix (NASDAQ:ENVX) has seen unusual options activity, with 75% of trades being bullish. The stock is currently down 6.68% at $9.92, and analysts have set price targets ranging from $15 to $30. The options activity suggests a price range of $5 to $13.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 8:45 pm

COMP

Compass projects Q4 sales between $1.225 billion and $1.325 billion, slightly above the $1.24 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:44 pm

NXT

Nextracker shares rose following the release of strong Q2 financial results and an increase in FY25 GAAP and adjusted EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:44 pm

PCOR

Procore Technologies has announced its FY24 revenue guidance to be between $1.146 billion and $1.148 billion, surpassing the previous estimate of $1.14 billion.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:44 pm

GRBK

Green Brick Partners reported Q3 2024 earnings per share of $1.98, missing the analyst estimate of $2.07. Sales were $523.66 million, below the expected $541.67 million, but up 24.99% from last year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:44 pm

CORT

Corcept Therapeutics shares declined following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:43 pm

LMND

Lemonade (NYSE:LMND) reported Q3 2024 results with a GAAP EPS of $(0.95), beating the estimate of $(0.97). Sales reached $136.60M, surpassing the $129.16M estimate and marking a 19.30% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:43 pm

BMEA

Biomea Fusion presented preclinical data showing that icovamenib enhances the effectiveness of GLP-1-based therapies, potentially improving insulin secretion and glycemic control in diabetes patients. They also introduced BMF-650, a promising next-generation GLP-1 receptor agonist candidate.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:43 pm

CFLT

Confluent shares rose following the release of their Q3 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:43 pm